Big Pharma has slowed down their buy outs of late because
Big Pharma has slowed down their buy outs of late because of using early promising phase 2 data that never came to fruition and many different pharmaceutical companies lost billions on buying on speculation. They want to see results that will be a guarantee or already have a BLA approved before buying. I think their motto became fool me once shame on you... fool me twice shame on me...
Big Pharma can’t stand any more buy out shame. They want the real deal already approved with BLA’s before they convince their board to buy a biotech. That is until recent covid purchases. But what drug has been a knock out? What drug will be the one to save many lives? Are they buying the right biotech? So many to choose from. Is it a last man standing for Severe to Critical? I think not...
It’s a great thing that we as Cytodyn have so many irons in the fire. Makes us really expensive after our first BLA achieves approval with so many more on the cusp of the pipeline just waiting for Mr. Rahman to file. Let’s think about this... filing for 8 approvals by either EUA or BLA and throw in a possible BTD. By the time Vyrologix is realized as a gem... it will be a possible mega equal to most big Pharma.
Then maybe a possible merger. The potential numbers by years end of $75-$100 makes us very expensive to buy. If we throw in the BTD for cancer in a 96 billion dollar market... We don’t need any stinking merger. We will be larger than half of the big Pharma’s by then. Maybe we buy out a few of them?
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hong Kong Wine & Dine Festival Returns This October HONG KONG, an anticipated gastronomic spectacle is set for the latter part of October. The Hong Kong Wine & Dine Festival will take place from 23 to 26 October 2025 at the iconic Central Harbourfront. This annual celebration is designed to showcase the best in culinary arts and exquisite wines, offering something special...
Continue Reading
Danaher Sets Date for Q3 2024 Earnings Conference Call Danaher Corporation (NYSE: DHR) has announced the date for its highly anticipated quarterly earnings conference call. This event is significant for investors and stakeholders who keep a close eye on the company's developments. Earnings Call Details The earnings call is set for an upcoming Tuesday morning, during which...
Continue Reading
UniQure Stock Reaches New Heights UniQure NV (QURE) has exciting news as its stock recently touched an impressive 52-week high of $18.5. This remarkable milestone is a testament to the company's resilient growth strategy and innovative advancements in the biotechnology industry. With a market capitalization reaching $885 million, the stock has seen an astonishing rise of...
Continue Reading
MedCana Enters Negotiations for Cannabis Supply Agreement MedCana, a prominent player in the pharmaceutical-grade cannabis landscape, is making headlines with an exciting new development from its subsidiary in Colombia. The company is set to negotiate a substantial supply agreement worth between $1.2 million and $2.4 million annually. This agreement marks a significant...
Continue Reading
Mouawad Teams Up with OCTA Properties for Luxe Residences OCTA Properties has been selected as the global licensee for residences branded by Mouawad, bringing the brand's legacy of timeless elegance into the realm of premium real estate. This partnership marks an exciting new chapter in Mouawad's prestigious journey in luxury development. A Landmark Collaboration Mouawad,...
Continue Reading